Physician profile
Tyler A Simowitz
NPI 1053997064
$983.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $712.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.97 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $166.27 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.46 | 2021-2022 | |
| Amgen INC. | $55.84 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $49.25 | 2021-2022 | |
| Glaxosmithkline, LLC. | $43.13 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $42.35 | 2022 | |
| Paratek Pharmaceuticals, INC. | $41.72 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.36 | 2022 | |
| Lilly USA, LLC | $28.71 | 2022 | |
| Merck Sharp & Dohme LLC | $26.26 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2022 | |
| Optinose US, INC. | $14.96 | 2021 | |
| Esperion Therapeutics, INC. | $12.95 | 2022 | |
| Novo Nordisk INC | $12.34 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Simowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.